Put Options

15 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$113.33 - $163.85 $679,980 - $983,100
-6,000 Reduced 14.71%
34,800 $5.5 Million
Q1 2024

May 14, 2024

SELL
$93.7 - $141.53 $1.54 Million - $2.32 Million
-16,400 Reduced 28.67%
40,800 $5.28 Million
Q4 2023

Feb 13, 2024

BUY
$67.31 - $124.76 $1.95 Million - $3.62 Million
29,000 Added 102.84%
57,200 $5.52 Million
Q3 2023

Nov 13, 2023

BUY
$102.5 - $123.59 $2.23 Million - $2.69 Million
21,800 Added 340.63%
28,200 $3.42 Million
Q2 2023

Aug 11, 2023

SELL
$106.4 - $157.19 $383,040 - $565,884
-3,600 Reduced 36.0%
6,400 $732,000
Q1 2023

May 12, 2023

BUY
$117.53 - $155.99 $399,602 - $530,366
3,400 Added 51.52%
10,000 $1.38 Million
Q4 2022

Feb 10, 2023

SELL
$100.86 - $132.13 $1.54 Million - $2.02 Million
-15,300 Reduced 69.86%
6,600 $855,000
Q3 2022

Nov 14, 2022

BUY
$75.71 - $119.24 $499,685 - $786,984
6,600 Added 43.14%
21,900 $2.42 Million
Q2 2022

Aug 12, 2022

BUY
$62.69 - $88.44 $714,666 - $1.01 Million
11,400 Added 292.31%
15,300 $1.15 Million
Q1 2020

May 14, 2020

SELL
$82.38 - $131.64 $4.65 Million - $7.44 Million
-56,500 Reduced 93.54%
3,900 $381,000
Q4 2019

Feb 13, 2020

BUY
$76.53 - $135.58 $757,647 - $1.34 Million
9,900 Added 19.6%
60,400 $7.79 Million
Q3 2019

Nov 08, 2019

BUY
$72.81 - $156.91 $1.83 Million - $3.94 Million
25,100 Added 98.82%
50,500 $3.8 Million
Q2 2019

Aug 14, 2019

SELL
$112.21 - $151.95 $224,420 - $303,900
-2,000 Reduced 7.3%
25,400 $3.86 Million
Q1 2019

May 15, 2019

BUY
$106.67 - $151.68 $789,358 - $1.12 Million
7,400 Added 37.0%
27,400 $3.27 Million
Q4 2018

Feb 13, 2019

BUY
$97.32 - $148.76 $1.95 Million - $2.98 Million
20,000 New
20,000 $2.18 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.9B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Peak6 Investments LLC Portfolio

Follow Peak6 Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peak6 Investments LLC with notifications on news.